1,415
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma

, , , &
Article: 2182619 | Received 15 Feb 2023, Accepted 15 Feb 2023, Published online: 23 Feb 2023

References

  • Shah SR, Tran TM. Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs. 2007;67(13):1869–1881.
  • Blair HA. Lenalidomide: a review in previously treated follicular lymphoma. Drugs. 2020;80(13):1337–1344.
  • Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683–687.
  • Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017;77(5):505–520.
  • Ferrazzi A, Zambello R, Russo I, et al. Psoriasis induced by thalidomide in a patient with multiple myeloma. BMJ Case Rep. 2014;2014(jun27 1):bcr2014204469–bcr2014204469.
  • D'Arena G, Galdo G, Musto P. Thalidomide-induced psoriasis in a patient with multiple myeloma. Postgrad Med J. 2019;95(1121):171.
  • Dobson CM, Parslew RA. Exacerbation of psoriasis by thalidomide in behçet’s syndrome. Br J Dermatol. 2003;149(2):432–433.
  • Varma K, Finlay AY. Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme. Br J Dermatol. 2006;154(4):789–790.
  • Mylonas A, Conrad C. Psoriasis: classical vs. Paradoxical. The Yin-Yang of TNF and type I interferon. Front Immunol. 2018;9:2746.